Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARQT trades at $20.42 with a market cap of $2.51B and a P/E ratio of -676.83. ARQT moved +5.00% today. Year to date, ARQT is -32.22%; over the trailing twelve months it is +41.08%. Its 52-week range spans $8.03 to $31.77. Analyst consensus is strong buy with an average price target of $34.63. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ARQT moved +5.00% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $20.42 |
| Market Cap | $2.51B |
| P/E Ratio | -676.83 |
| EPS | $-0.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.77 |
| 52-Week Low | $8.03 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $415.62M |
| Net Income | $-2.38M |
| Gross Margin | 90.94% |
8 analysts cover ARQT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.63.